Dermatologic adverse events associated with targeted therapies for melanoma-Reference-Cited by-同舟云学术

Dermatologic adverse events associated with targeted therapies for melanoma

Published:2021-11-02 Issue: Volume: Page:1-11
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Scarpato Luigi¹^ORCID,Festino Lucia¹^ORCID,Vanella Vito¹^ORCID,Madonna Gabriele¹^ORCID,Mastroianni Massimo²,Palla Marco¹^ORCID,Ascierto Paolo Antonio¹^ORCID

Affiliation:

1. Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

2. Department of Otolaryngology Surgery and Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

Funder

National Natural Science Foundation of China

GuangDong Basic and Applied Basic Research Foundation

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.1986000

Reference90 articles.

1. Global Cancer Observatory. https://gco.iarc.fr.

2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

3. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

5. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective;Journal of Cancer Research and Clinical Oncology;2024-05-14